Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Postmenopausal women with ovarian cysts detected on ultrasound are not at increased risk of developing ovarian cancer or, for that matter, breast or…
NEW YORK (Reuters Health) – For removal of uterine contents during the second trimester, dilation and evacuation (D&E) appears to prompt fewer complications and may be more cost-effective…
NEW YORK (Reuters Health) – A new report concludes that expectant management of severe preeclampsia occurring before 34 weeks gestation is appropriate in selected cases. It can prolong…
NEW YORK (Reuters Health) – Over the past nearly 30 years, survivors of myocardial infarction have suffered an increasing rate of osteoporotic fractures, a new population-based cohort study…
NEW YORK (Reuters Health) – For women giving birth, a high-dose oxytocin regimen results in a shorter duration of labor without increasing the c-section rate or adversely affecting…
NEW YORK (Reuters Health) – In young women with breast cancer, temporary ovarian suppression by the gonadotropin-releasing hormone analogue triptorelin during chemotherapy reduces the occurrence of premature menopause,…
NEW YORK (Reuters Health) – In postmenopausal women with node-positive early breast cancer, substituting docetaxel for epirubicin for the last three cycles of chemotherapy may improve outcome without…
NEW YORK (Reuters Health) – Frenotomy in newborns with significant ankyloglossia rapidly improves breastfeeding scores and reduces maternal nipple pain, according to the results of a randomized trial…
NEW YORK (Reuters Health) – When used as adjuvant therapy in high-risk breast cancer or as primary treatment for metastatic breast cancer, high-dose chemotherapy (HDC) with autologous stem-cell…
NEW YORK (Reuters Health) – The levonorgestrel-releasing intrauterine system (LNG-IUS) is as effective as systemic progestogen regimens for endometrial protection in women taking estrogen replacement therapy for menopausal…
